Bianca Caliò
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bianca Caliò has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Fanciulli
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
4 shared publications - Fabian Leys
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Klaus Seppi
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Stefan Kiechl
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Werner Poewe
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Anette Schrag
Department of Clinical and Movement Neurosciences, University College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wiley in Movement Disorders
Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases. Objective: To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA. Methods: EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages. Results: Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression. Conclusions: This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 6 November 2026
- Published by Wiley in Movement Disorders
Open AccessStage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases. Objective: To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA. Methods: EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages. Results: Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression. Conclusions: This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 5 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (7) , 1758-1760
Multimodal Treatment of Neck Pain in Multiple System Atrophy
- 5 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (7) , 1758-1760
Open AccessMultimodal Treatment of Neck Pain in Multiple System Atrophy
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (7)
Delayed orthostatic hypotension in Parkinson’s disease and in the general ageing population
Objective: Delayed orthostatic hypotension (dOH) is defined by a sustained blood pressure (BP) fall ≥20/10 mmHg occurring beyond 3 minutes in the upright position, whose clinical relevance is yet undetermined. We investigated frequency, associated features and treatment strategies of dOH in Parkinson’s Disease (PD) and ageing individuals with history of syncope or orthostatic intolerance. Methods: We retrospectively studied 213 individuals with PD and 213 age-matched individuals without parkinsonism referred for tilt-table testing to the Innsbruck and Florence Dysautonomia centres. In both cohorts, we reviewed the medical records of the 6 months before testing for history of syncope and falls, and of the 6 months afterwards for the recommended dOH treatment and clinical outcome. Results: dOH was twice as frequent in PD than in ageing individuals [18% versus 9%; OR = 2.9 (95 CI.: 1.3–6.5), P = .007]. Upon prolonged head-up tilt, PD individuals showed a more severe systolic BP fall (P < .001). PD individuals with history of syncope also exhibited a sustained systolic BP fall from the 3rd minute of head-up tilt onward compared to those without (P = .014). Both non-pharmacological and pharmacological OH treatment strategies were associated with symptomatic improvement at follow-up. Conclusions: In PD individuals referred to tertiary settings, tilt-table testing more frequently disclosed dOH compared to age-matched individuals without parkinsonism. In PD, dOH is mainly driven by a progressive orthostatic systolic BP fall, increasing the risk of syncope. Given its prevalence and the potential for effective treatment, dOH should be actively screened for in clinical practice.
- 1 July 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (7)
Open AccessDelayed orthostatic hypotension in Parkinson’s disease and in the general ageing population
Objective: Delayed orthostatic hypotension (dOH) is defined by a sustained blood pressure (BP) fall ≥20/10 mmHg occurring beyond 3 minutes in the upright position, whose clinical relevance is yet undetermined. We investigated frequency, associated features and treatment strategies of dOH in Parkinson’s Disease (PD) and ageing individuals with history of syncope or orthostatic intolerance. Methods: We retrospectively studied 213 individuals with PD and 213 age-matched individuals without parkinsonism referred for tilt-table testing to the Innsbruck and Florence Dysautonomia centres. In both cohorts, we reviewed the medical records of the 6 months before testing for history of syncope and falls, and of the 6 months afterwards for the recommended dOH treatment and clinical outcome. Results: dOH was twice as frequent in PD than in ageing individuals [18% versus 9%; OR = 2.9 (95 CI.: 1.3–6.5), P = .007]. Upon prolonged head-up tilt, PD individuals showed a more severe systolic BP fall (P < .001). PD individuals with history of syncope also exhibited a sustained systolic BP fall from the 3rd minute of head-up tilt onward compared to those without (P = .014). Both non-pharmacological and pharmacological OH treatment strategies were associated with symptomatic improvement at follow-up. Conclusions: In PD individuals referred to tertiary settings, tilt-table testing more frequently disclosed dOH compared to age-matched individuals without parkinsonism. In PD, dOH is mainly driven by a progressive orthostatic systolic BP fall, increasing the risk of syncope. Given its prevalence and the potential for effective treatment, dOH should be actively screened for in clinical practice.
- Open Access
- 24 May 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (5) , 903-917
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy
Multiple system atrophy (MSA) represents a management challenge due to its variable clinical presentation, and lack of established multidisciplinary care protocols. In advanced stages, physical barriers often prevent access to specialized care, leaving patients and caregivers to face complications and fear alone. This 18-month, monocentric, open-label study evaluates the impact of a personalized, multidisciplinary treatment, integrating mobile palliative care, on the quality of life (QoL, measured by EQ-5D-5L indices) of MSA individuals compared to a matched historical European MSA cohort. Forty-six participants will undergo baseline clinical, psychological, and neuro-rehabilitation assessments, along with an online interview to identify individual healthcare preferences. These assessments will guide personalized therapeutic plans, including palliative care, self-directed physio-, speech, and occupational exercises, based on operational protocols informed by evidence and good clinical practice. Six-, 12-, and 18-month follow-ups will reassess needs and adapt plans to address disease progression and changing preferences, ensuring continuous personalization. Repeated interviews at month-12, phone-calls and satisfaction surveys at month-1, 7, 13, and 18 will monitor compliance, identify barriers, and gather feedback. A subgroup of 23 participants will be block-wise randomized to additionally receive monthly and on-demand telemedicine visits for tailored support. Informal caregivers will join an 18-month observational study assessing their QoL and burden through repeated evaluations, offering insights into evolving challenges. We expect that multidisciplinary, patient-centered care with integrated mobile palliative and telemedicine support helps to warrant continuity of care and improve the QoL of MSA individuals throughout the disease course. Its acceptance, safety, and cost-effectiveness will be also assessed.
- 24 May 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (5) , 903-917
Open AccessMeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy
Multiple system atrophy (MSA) represents a management challenge due to its variable clinical presentation, and lack of established multidisciplinary care protocols. In advanced stages, physical barriers often prevent access to specialized care, leaving patients and caregivers to face complications and fear alone. This 18-month, monocentric, open-label study evaluates the impact of a personalized, multidisciplinary treatment, integrating mobile palliative care, on the quality of life (QoL, measured by EQ-5D-5L indices) of MSA individuals compared to a matched historical European MSA cohort. Forty-six participants will undergo baseline clinical, psychological, and neuro-rehabilitation assessments, along with an online interview to identify individual healthcare preferences. These assessments will guide personalized therapeutic plans, including palliative care, self-directed physio-, speech, and occupational exercises, based on operational protocols informed by evidence and good clinical practice. Six-, 12-, and 18-month follow-ups will reassess needs and adapt plans to address disease progression and changing preferences, ensuring continuous personalization. Repeated interviews at month-12, phone-calls and satisfaction surveys at month-1, 7, 13, and 18 will monitor compliance, identify barriers, and gather feedback. A subgroup of 23 participants will be block-wise randomized to additionally receive monthly and on-demand telemedicine visits for tailored support. Informal caregivers will join an 18-month observational study assessing their QoL and burden through repeated evaluations, offering insights into evolving challenges. We expect that multidisciplinary, patient-centered care with integrated mobile palliative and telemedicine support helps to warrant continuity of care and improve the QoL of MSA individuals throughout the disease course. Its acceptance, safety, and cost-effectiveness will be also assessed.
- Open Access
- 17 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (2) , 157
Age at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson’s Disease: A Monocentric Retrospective Study
The interactions between the age at onset with other pathogenic mechanisms and the interplays between the disease progression and the aging processes in Parkinson’s disease (PD) remain undefined, particularly during the first years of illness. Here, we retrospectively investigated the clinical presentation and evolution of the motor and non-motor symptoms and treatment-related complications during the first 5 years of illness in subjects categorized according to age at onset. A total of 131 subjects were divided into “Early-Onset-PD” (EOPD; onset ≤49 years), “Middle-Onset-PD” (MOPD; onset 50–69 years) and “Late-Onset-PD” (LOPD; onset ≥70 years). The T0 visit was set at the time of the clinical diagnosis; the T1 visit was 5 years (±5 months) later. At T0, there were no significant differences in the motor features among the groups. At T1, the LOPD patients displayed a significantly higher frequency of gait disturbances and a higher frequency of postural instability. Moreover, at T1, the LOPD subjects reported a significantly higher frequency of non-motor symptoms; in particular, cardiovascular, cognitive and neuropsychiatric domains. The presented results showed a significantly different progression of motor and non-motor symptoms in the early course of PD according to the age at onset. These findings contribute to the definition of the role of age at onset on disease progression and may be useful for the pharmacological and non-pharmacological management of PD.
- 17 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (2) , 157
Open AccessAge at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson’s Disease: A Monocentric Retrospective Study
The interactions between the age at onset with other pathogenic mechanisms and the interplays between the disease progression and the aging processes in Parkinson’s disease (PD) remain undefined, particularly during the first years of illness. Here, we retrospectively investigated the clinical presentation and evolution of the motor and non-motor symptoms and treatment-related complications during the first 5 years of illness in subjects categorized according to age at onset. A total of 131 subjects were divided into “Early-Onset-PD” (EOPD; onset ≤49 years), “Middle-Onset-PD” (MOPD; onset 50–69 years) and “Late-Onset-PD” (LOPD; onset ≥70 years). The T0 visit was set at the time of the clinical diagnosis; the T1 visit was 5 years (±5 months) later. At T0, there were no significant differences in the motor features among the groups. At T1, the LOPD patients displayed a significantly higher frequency of gait disturbances and a higher frequency of postural instability. Moreover, at T1, the LOPD subjects reported a significantly higher frequency of non-motor symptoms; in particular, cardiovascular, cognitive and neuropsychiatric domains. The presented results showed a significantly different progression of motor and non-motor symptoms in the early course of PD according to the age at onset. These findings contribute to the definition of the role of age at onset on disease progression and may be useful for the pharmacological and non-pharmacological management of PD.
- Open Access
Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables
Commercial smartwatches could be useful for step counting and monitoring ambulatory activity. However, in Parkinson’s disease (PD) patients, an altered gait, pharmacological condition, and symptoms lateralization may affect their accuracy and potential usefulness in research and clinical routine. Steps were counted during a 6 min walk in 47 patients with PD and 47 healthy subjects (HS) wearing a Garmin Vivosmart 4 (GV4) on each wrist. Manual step counting was used as a reference. An inertial sensor (BTS G-Walk), placed on the lower back, was used to compute spatial-temporal gait parameters. Intraclass correlation coefficient (ICC) and mean absolute percentage error (MAPE) were used for accuracy evaluation and the Spearman test was used to assess the correlations between variables. The GV4 overestimated steps in PD patients with only a poor-to-moderate agreement. The OFF pharmacological state and wearing the device on the most-affected body side led to an unacceptable accuracy. The GV4 showed an excellent agreement and MAPE in HS at a self-selected speed, but an unacceptable performance at a slow speed. In PD patients, MAPE was not associated with gait parameters and clinical variables. The accuracy of commercial smartwatches for monitoring step counting might be reduced in PD patients and further influenced by the pharmacological condition and placement of the device.
Open AccessStep-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables
Commercial smartwatches could be useful for step counting and monitoring ambulatory activity. However, in Parkinson’s disease (PD) patients, an altered gait, pharmacological condition, and symptoms lateralization may affect their accuracy and potential usefulness in research and clinical routine. Steps were counted during a 6 min walk in 47 patients with PD and 47 healthy subjects (HS) wearing a Garmin Vivosmart 4 (GV4) on each wrist. Manual step counting was used as a reference. An inertial sensor (BTS G-Walk), placed on the lower back, was used to compute spatial-temporal gait parameters. Intraclass correlation coefficient (ICC) and mean absolute percentage error (MAPE) were used for accuracy evaluation and the Spearman test was used to assess the correlations between variables. The GV4 overestimated steps in PD patients with only a poor-to-moderate agreement. The OFF pharmacological state and wearing the device on the most-affected body side led to an unacceptable accuracy. The GV4 showed an excellent agreement and MAPE in HS at a self-selected speed, but an unacceptable performance at a slow speed. In PD patients, MAPE was not associated with gait parameters and clinical variables. The accuracy of commercial smartwatches for monitoring step counting might be reduced in PD patients and further influenced by the pharmacological condition and placement of the device.